Фреманезумаб може да преполови број напада мигрене код деце
Неспецифично антитело фреманезумаб може да смањи за 50 посто број напада мигрене код деце, показала је најновија међународна клиничка студија у којој је учествовао ИРЦЦС Сан Рафаеле у Риму, преносе данас италијански медији.
TL;DR
- Fremanezumab, a non-specific antibody, may decrease migraine attacks in children by 50%.
- This finding comes from an international clinical study involving IRCCS San Raffaele in Rome.
- Fremanezumab is a monoclonal antibody targeting CGRP and is approved by the FDA for pediatric migraine prevention.
- It is the first anti-CGRP therapy approved for both adults and children.
- The study, published in the New England Journal of Medicine, included 237 patients aged 6-17 with episodic migraines.
- Over half of the participants experienced at least a 50% reduction in migraine frequency after three months of treatment.
- No significant side effects were reported.
- European approval for fremanezumab is currently pending.